The FDA approved the gene therapy Zolgensma to treat children with a severe form of spinal muscular atrophy. The drug costs $2.125 million for a one-time treatment, CBS News reported.
from WebMD Health https://www.webmd.com/drug-medication/news/20190807/fda-pricey-drug-approved-on-manipulated-data?src=RSS_PUBLIC
0 Comments:
Post a Comment